Skip to main content
Erschienen in:

02.10.2024 | Clinical Investigation

Analysis of clinical features and outcomes in patients with ocular myasthenia gravis according to anti-acetylcholine receptor antibody-seropositivity

verfasst von: Byung Joo Lee, Jimin Park, Hyosook Ahn, Hyun Taek Lim

Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To comparatively analyze the clinical characteristics of patients with ocular myasthenia gravis (OMG) referred to an ophthalmology clinic, according to anti-acetylcholine receptor antibody (AchR Ab)-seropositivity.

Study design

Retrospective Cohort Study.

Methods

Medical records of patients with OMG who presented to a tertiary eye care center between 2003 and 2020 were retrospectively reviewed. Demographics, ophthalmologic characteristics, response to medical treatment, presence of autoimmune thyroid disease and thyroid autoantibody were compared between the AchR Ab seropositive and seronegative groups.

Results

A total of 130 patients with OMG were identified; among them, 46 patients (35.4%) had autoantibody against acetylcholine receptors. The mean age at symptom onset was 42.4 ± 18.9 years. There were no differences in mean age at symptom onset, gender ratio, and mean follow-up period between patients with seropositive and seronegative OMG. Graves ophthalmopathy was significantly more frequent in seronegative patients (p = 0.04), while thymic disease (p < 0.01) was more frequent in seropositive patients (p < 0.01). Among patients with seropositive OMG, 52.3% showed a good response to medical treatment, while only 31.4% of the seronegative patients were classified as good responders (p = 0.01). Thyroid dysfunction was found in 27.4% patients with OMG and the proportion of thyroid dysfunction was not different according to anti-acetylcholine receptor antibody-seropositivity.

Conclusion

Seropositivity to acetylcholine receptor antibody is associated with a better response to medical treatment and lower risk of concomitant autoimmune thyroid disease in patients with OMG.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141–9.CrossRefPubMed Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141–9.CrossRefPubMed
2.
Zurück zum Zitat Galassi G, Mazzoli M, Ariatti A, Kaleci S, Valzania F, Nichelli PF. Antibody profile may predict outcome in ocular myasthenia gravis. Acta Neurol Belg. 2018;118:435–43.CrossRefPubMed Galassi G, Mazzoli M, Ariatti A, Kaleci S, Valzania F, Nichelli PF. Antibody profile may predict outcome in ocular myasthenia gravis. Acta Neurol Belg. 2018;118:435–43.CrossRefPubMed
3.
Zurück zum Zitat Nagaishi A, Narita T, Woodhall M, Jacobson L, Waters P, Irani SR, et al. Autoantibodies in Japanese patients with ocular myasthenia gravis. Muscle Nerve. 2021;63:262–7.CrossRefPubMed Nagaishi A, Narita T, Woodhall M, Jacobson L, Waters P, Irani SR, et al. Autoantibodies in Japanese patients with ocular myasthenia gravis. Muscle Nerve. 2021;63:262–7.CrossRefPubMed
4.
Zurück zum Zitat Birmanns B, Brenner T, Abramsky O, Steiner I. Seronegative myasthenia gravis: clinical features, response to therapy and synthesis of acetylcholine receptor antibodies in vitro. J Neurol Sci. 1991;102:184–9.CrossRefPubMed Birmanns B, Brenner T, Abramsky O, Steiner I. Seronegative myasthenia gravis: clinical features, response to therapy and synthesis of acetylcholine receptor antibodies in vitro. J Neurol Sci. 1991;102:184–9.CrossRefPubMed
5.
Zurück zum Zitat Evoli A, Batocchi AP, Lo Monaco M, Servidei S, Padua L, Majolini L, et al. Clinical heterogeneity of seronegative myasthenia gravis. Neuromuscul Disord. 1996;6:155–61.CrossRefPubMed Evoli A, Batocchi AP, Lo Monaco M, Servidei S, Padua L, Majolini L, et al. Clinical heterogeneity of seronegative myasthenia gravis. Neuromuscul Disord. 1996;6:155–61.CrossRefPubMed
6.
7.
Zurück zum Zitat Mao ZF, Yang LX, Mo XA, Qin C, Lai YR, He NY, et al. Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci. 2011;121:121–9.CrossRefPubMed Mao ZF, Yang LX, Mo XA, Qin C, Lai YR, He NY, et al. Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci. 2011;121:121–9.CrossRefPubMed
8.
Zurück zum Zitat Kubiszewska J, Szyluk B, Szczudlik P, Bartoszewicz Z, Dutkiewicz M, Bielecki M, et al. Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course. Brain Behav. 2016;6:e00537.CrossRefPubMedPubMedCentral Kubiszewska J, Szyluk B, Szczudlik P, Bartoszewicz Z, Dutkiewicz M, Bielecki M, et al. Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course. Brain Behav. 2016;6:e00537.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Ratanakorn D, Vejjajiva A. Long-term follow-up of myasthenia gravis patients with hyperthyroidism. Acta Neurol Scand. 2002;106:93–8.CrossRefPubMed Ratanakorn D, Vejjajiva A. Long-term follow-up of myasthenia gravis patients with hyperthyroidism. Acta Neurol Scand. 2002;106:93–8.CrossRefPubMed
11.
Zurück zum Zitat Kiessling WR, Pflughaupt KW, Ricker K, Haubitz I, Mertens HG. Thyroid function and circulating antithyroid antibodies in myasthenia gravis. Neurology. 1981;31:771–4.CrossRefPubMed Kiessling WR, Pflughaupt KW, Ricker K, Haubitz I, Mertens HG. Thyroid function and circulating antithyroid antibodies in myasthenia gravis. Neurology. 1981;31:771–4.CrossRefPubMed
12.
Zurück zum Zitat Toth C, McDonald D, Oger J, Brownell K. Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Acta Neurol Scand. 2006;114:124–32.CrossRefPubMed Toth C, McDonald D, Oger J, Brownell K. Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Acta Neurol Scand. 2006;114:124–32.CrossRefPubMed
13.
Zurück zum Zitat Lopomo A, Berrih-Aknin S. Autoimmune thyroiditis and Myasthenia Gravis. Front Endocrinol (Lausanne). 2017;8:169.CrossRefPubMed Lopomo A, Berrih-Aknin S. Autoimmune thyroiditis and Myasthenia Gravis. Front Endocrinol (Lausanne). 2017;8:169.CrossRefPubMed
14.
Zurück zum Zitat Sun L, Meng Y, Xie Y, Zhang H, Zhang Z, Wang X, et al. CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese population. PLoS ONE. 2014;9:e101986.CrossRefPubMedPubMedCentral Sun L, Meng Y, Xie Y, Zhang H, Zhang Z, Wang X, et al. CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese population. PLoS ONE. 2014;9:e101986.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Claytor B, Li Y. Challenges in diagnosing coexisting ocular myasthenia gravis and thyroid eye disease. Muscle Nerve. 2021;63:631–9.CrossRefPubMed Claytor B, Li Y. Challenges in diagnosing coexisting ocular myasthenia gravis and thyroid eye disease. Muscle Nerve. 2021;63:631–9.CrossRefPubMed
16.
17.
Zurück zum Zitat Chatzistefanou KI, Kouris T, Iliakis E, Piaditis G, Tagaris G, Katsikeris N, et al. The ice pack test in the differential diagnosis of myasthenic diplopia. Ophthalmology. 2009;116:2236–43.CrossRefPubMed Chatzistefanou KI, Kouris T, Iliakis E, Piaditis G, Tagaris G, Katsikeris N, et al. The ice pack test in the differential diagnosis of myasthenic diplopia. Ophthalmology. 2009;116:2236–43.CrossRefPubMed
18.
Zurück zum Zitat An R, Li Y, Yang B, Wang H, Xu Y. Rare co-occurrence of ocular myasthenia gravis and thyroid-Associated Orbitopathy (Ophthalmopathy) in an individual with hypothyroidism. Front Endocrinol (Lausanne). 2018;9:801.CrossRefPubMed An R, Li Y, Yang B, Wang H, Xu Y. Rare co-occurrence of ocular myasthenia gravis and thyroid-Associated Orbitopathy (Ophthalmopathy) in an individual with hypothyroidism. Front Endocrinol (Lausanne). 2018;9:801.CrossRefPubMed
19.
Zurück zum Zitat Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci. 2008;1132:76–83.CrossRefPubMed Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci. 2008;1132:76–83.CrossRefPubMed
20.
Zurück zum Zitat Hamedani AG, Pistilli M, Singhal S, Shindler KS, Avery RA, Tamhankar MA. Outcomes after Transcervical Thymectomy for Ocular Myasthenia gravis: a Retrospective Cohort Study with Inverse Probability Weighting. J Neuroophthalmol. 2020;40:8–14.CrossRefPubMedPubMedCentral Hamedani AG, Pistilli M, Singhal S, Shindler KS, Avery RA, Tamhankar MA. Outcomes after Transcervical Thymectomy for Ocular Myasthenia gravis: a Retrospective Cohort Study with Inverse Probability Weighting. J Neuroophthalmol. 2020;40:8–14.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Roberts PF, Venuta F, Rendina E, De Giacomo T, Coloni GF, Follette DM, et al. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg. 2001;122:562–8.CrossRefPubMed Roberts PF, Venuta F, Rendina E, De Giacomo T, Coloni GF, Follette DM, et al. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg. 2001;122:562–8.CrossRefPubMed
22.
Zurück zum Zitat Liu X, Zhou W, Hu J, Hu M, Gao W, Zhang S, Zeng W. Prognostic predictors of remission in ocular myasthenia after thymectomy. J Thorac Dis. 2020;12:422–30.CrossRefPubMedPubMedCentral Liu X, Zhou W, Hu J, Hu M, Gao W, Zhang S, Zeng W. Prognostic predictors of remission in ocular myasthenia after thymectomy. J Thorac Dis. 2020;12:422–30.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Peeler CE, De Lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT. Clinical utility of acetylcholine receptor antibody testing in Ocular Myasthenia Gravis. JAMA Neurol. 2015;72:1170–4.CrossRefPubMedPubMedCentral Peeler CE, De Lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT. Clinical utility of acetylcholine receptor antibody testing in Ocular Myasthenia Gravis. JAMA Neurol. 2015;72:1170–4.CrossRefPubMedPubMedCentral
Metadaten
Titel
Analysis of clinical features and outcomes in patients with ocular myasthenia gravis according to anti-acetylcholine receptor antibody-seropositivity
verfasst von
Byung Joo Lee
Jimin Park
Hyosook Ahn
Hyun Taek Lim
Publikationsdatum
02.10.2024
Verlag
Springer Japan
Erschienen in
Japanese Journal of Ophthalmology / Ausgabe 6/2024
Print ISSN: 0021-5155
Elektronische ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-024-01125-8

Neu im Fachgebiet Augenheilkunde

Künstliche Intelligenz in der Medizin – Chancen und Risiken aus ethischer Sicht

Bildgebende Fächer wie die Augenheilkunde bieten vielfältige Möglichkeiten für den nutzbringenden Einsatz künstlicher Intelligenz (KI). Die Auswertung von Bildern und Daten mittels trainierter Algorithmen besitzt das Potenzial, die …

Okuläre Graft-versus-Host-Disease

Die okuläre Graft-versus-Host-Erkrankung („graft-versus-host disease“ [GVHD]) nach allogener hämatopoetischer Stammzelltransplantation (HSCT) stellt überwiegend eine entzündliche und destruierende Augenoberflächenerkrankung mit zunehmender …

Kataraktchirurgie in Subsahara-Afrika – Möglichkeiten und Grenzen

Die Bedeutung von Sehbeeinträchtigung und Blindheit für Individuen und Gesellschaften hat in den letzten Jahren ein hohes Maß an Aufmerksamkeit erfahren. Wesentliche Aspekte dieser Thematik sind im World report on vision der …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.